Edgewise Therapeutics, Inc.
EWTX
Rankning i aktier
#3837
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing... Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
Aktiekurs
$39.70
Senast synkroniserad: 2026-10-21
Marknadsvärde
$4.27B
Förändring (1 dag)
-0.12%
Förändring (1 år)
166.64%
Land
US
Handel Edgewise Therapeutics, Inc. (EWTX)
Kategori
Healthcare
Aktiekurshistorik för Edgewise Therapeutics, Inc. (EWTX)
Högsta slutkurs: $38.97 den 2026-10-01
Lägsta slutkurs: $32.43 den 2021-03-01
Lägsta slutkurs: $32.43 den 2021-03-01
Aktiekurshistorik för Edgewise Therapeutics, Inc. från 2021 till 2026
Årlig aktiekursutveckling
| År | Prestanda |
|---|---|
| 2026 (TTM) | 38.00% |
| 2025 | -20.97% |
| 2024 | 268.96% |
| 2023 | -1.80% |
| 2022 | -51.10% |
| 2021 | 0.00% |
Aktiekurs för liknande företag eller konkurrenter
| Företag | Aktiekurs | Förändring 1år% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $752.87 | 7.01% |
CH
|
